CRISPR Therapeutics AG — Director's Dealing 2016

Oct 18, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2016-10-18

Reporting Person: Dylan-Hyde Tyler (Chief Legal Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares	205204	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$12.57	2026-07-15	Common Shares (53333)		Direct
Stock Option (Right to Buy)	$12.57	2026-07-15	Common Shares (26667)		Direct

Footnotes

F1: This option was granted on July 15, 2016 with respect to 53,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.

F2: This performance-based option was granted on July 15, 2016 with respect to 26,667 Common Shares with 100% of the shares vesting within 12 months of the date of grant, subject to the satisfaction of mutually agreed upon performance metrics.